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Abstract
gp120 is a substrate for protein engineering both for HIV immunogen design and as a bait for
isolating anti-HIV antibodies from patient samples. In this work we describe the display of a
stripped core gp120 on the yeast cell surface. Validation against a panel of neutralizing antibodies
confirms that yeast-displayed gp120 presents the CD4 binding site in the correct conformation.
We map the epitope of the broadly neutralizing anti-gp120 antibody VRC01 using both a random
mutagenesis library and a defined mutant panel, and find the resultant epitope maps are consistent
with one another and with the crystallographically identified contact residues. Mapping the
VRC01-competitive antibodies b12 and b13 reveals energetic differences in their epitopes that are
not obvious from existing crystal structures. These data suggest mutation sets that abrogate
binding to broadly neutralizing antibodies with greater specificity than the canonical mutation
D368R, useful in rapidly assessing the nature of a vaccine response.
Introduction
Glycoprotein gp120 of the envelope spike of human immunodeficiency virus (HIV) is the
target of most anti-HIV antibodies generated upon infection or vaccination1,2. HIV mutates
rapidly and gp120 tolerates tremendous sequence variability, rendering the vast majority of
these antibodies ineffective, allowing the virus to evade immune recognition3. Certain
regions of gp120, such as the docking site of CD4, must be conserved for the virus to retain
fitness4. Antibodies that target these conserved epitopes have been shown to bind to and
block virus regardless of clade, thereby negating the virus’ main advantage1. Much of the
focus of current HIV vaccine research involves the isolation of new neutralizing antibodies,
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understanding their structure/function relationships, and designing immunogens intended to
elicit such antibodies by vaccination.
Advances in high-throughput screening techniques and new patient cohorts have led to an
explosion in the discovery of broadly neutralizing antibodies. Whereas five years ago there
were just a handful of known gp120-specific neutralizing antibodies—b12 against the CD4
binding site5,6, 2G12 against a conserved glycan motif7, and 17b and X5 against the
chemokine co-receptor binding site8-10—there are now dozens on the rapidly-growing
list11-14. Beyond just finding new neutralizing antibodies, analysis of patient antisera has
identified common neutralization-sensitive epitopes15-18; crystal structures provide insights
into the relationship between the structure of antibody-gp120 complexes and their
function19-21; deep sequencing has revealed the likely somatic hypermutation pathway by
which these antibodies evolved from the germ line22,23; and hypotheses about how these
antibodies compensate for monovalent binding to sparse trimeric spikes on the viral surface
have been tested24,25.
VRC01 is the gold standard antibody against the CD4 binding site, because it is one of the
broadest and most potent neutralizing antibodies discovered to date26. It was isolated from a
patient sample using a hybrid HIV/SIV gp120 that had been “resurfaced” to remove all HIV
epitopes except for the CD4 binding site. Similar screens with modified gp120 molecules
that exhibit differential binding is how most neutralizing antibodies are identified and
characterized27-29.
Modifications are also made to gp120 when designing an immunogen to elicit neutralizing
antibodies by vaccination30. Deliberate amino acid substitutions can, for example, lock the
flexible molecule into an “open” conformation and overcome the considerable entropic
penalty incurred upon binding31-33. Mutations can also disrupt antibody binding to irrelevant
surfaces and encode glycosylation sites to shield undesired epitopes34-36. Immunodominant
loops that distract from neutralizing epitopes can be removed entirely37,38.
Trimeric gp160 is an alternative to monomeric gp120 for many of these applications. It has
been shown that the monomer presents epitopes that are sterically inaccessible on the native
trimer, and the immune system elicits non-neutralizing antibodies to these monomer-specific
epitopes19.Additionally, some neutralizing antibodies recognize quaternary epitopes and
thus cannot be faithfully captured by monomeric gp12014. Soluble trimers have been
designed and used in in vitro screens and in vivo immunizations39,40. Engineered viruses are
also used to present gp120 in its native conformation15, but this requires additional safety
measures that are not amenable to every lab.
Most of the previously-described gp120 variants are made by rational design, sometimes
guided by computation, then individually constructed, secreted, and tested for binding by
ELISA35,41,42. Yeast surface display provides an alternative, simple and flexible method for
engineering complex glycoproteins43,44. Surface displayed proteins can be easily modified
by random or rational mutagenesis, and binding phenotypes assayed by flow cytometry. We
and others have engineered complex glycoprotein receptor ectodomains45,46, and validated
yeast surface display for fine resolution mapping of conformational epitopes47.
Despite its utility, yeast display has not yet been used to engineer gp120 for immunogens or
as bait for isolating neutralizing antibodies. In this work, we report the display of gp120 on
yeast, characterize its binding to a panel of broadly neutralizing antibodies and map the
epitopes of several of these antibodies, demonstrating the potential for yeast display to
accelerate immunogen design.
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Results
Display of gp120 on yeast. The gene for gp120 from HIV strain YU248 was subcloned into a
yeast display vector with a C-terminal Aga2p fusion partner (FIG 1A). Yeast displaying the
full protein did not bind to antibody b12 (data not shown), so extensive modifications were
made to strip the protein of flexible loops that might misfold or cause steric occlusion of the
b12 epitope (FIG 1A and Supplementary Table 1). These modifications are similar, though
not identical, to the original core gp120 crystalized in complex with CD449. The flexible
gp41-interactive regions at the N- and C-termini (aa 1-89, 493-511)50 were excised
entirely.The long hyper-variable loops3,51—V1/V2 (aa 124-198), V3 (aa 298-329), and the
bridging sheet β20/21 (aa 422-437)—were replaced with the short, glycosylated amino acid
linkers GNGS, GNGSG, and GGNGS respectively. An additional set of mutations (Q114N,
L116T) introduced an N-linked glycosylation sequence at a site previously identified as
important for masking an epitope on the V1/V2 stem35.
Despite thesemodifications, the resultant “stripped core” gp120 retains the structurally rigid
outer domain that has been extensively studied elsewhere4,52,53.The protein is expressed
well on the yeast surface (1×105 copies per cell; standard for yeast surface display) and
conserves the structure of the CD4 binding site as measured by binding to CD4 and to a
panel of neutralizing antibodies (FIG 1B, 1C).
Broadly neutralizing anti-gp120 antibodies VRC01, PGV04 (isolated from the same patient
as VRC01 but by a different protocol)26, and b125,6, as well as the non-neutralizing CD4-
directed antibodies b6 and b1354 were titrated on yeast displaying stripped core gp120 and
the binding measured by flow cytometry. The equilibrium binding constants ranged from 24
pM for b6 to 0.9 nM for PGV04 and b13. Yeast-displayed stripped core gp120 also bound
CD4-Fc with a binding constant of 5.6 nM, despite the removal of the bridging sheet that
comprises a substantial portion of the CD4 binding site. These binding data are consistent
with the single-digit nM affinities measured for CD4 binding site-directed antibodies to
several gp120 constructs by other methods26, and with binding of multivalent CD4
constructs to both “liganded” and “unliganded” conformations of gp120 20.
Other antibodies of interest in the field of HIV vaccine design were tested as well, but did
not bind to the stripped core construct (data not shown). Antibodies 17b and X5 that
recognize the chemokine receptor epitope on gp1208-10—called the CD4-induced or CD4i
epitope because it is only induced upon CD4 engagement—did not bind, which is expected
given that much of the CD4i epitope was removed when the bridging sheet was replaced
with a short linker. Non-neutralizing antibody F10555, whose crystal structure (PDB ID:
3HI1) indicates that it too makes significant contacts with the bridging sheet19, did not
bind.Antibodies PGT-121 and PGT-128, known to recognize an epitope on variable loop
V311,12, did not bind to the V3-less construct. Antibody 2G12, which recognizes an array
ofhigh-mannose glycans on the surface of gp12056-58also did not bind the stripped core
displayed on yeast.S. cerevisiae hyper-mannosylatesN-linked glycans and produces
glycoforms different from those recognized by 2G1259.Others have engineered S.
cerevisiaesuch that its glycoproteins are recognized by 2G1260; display of stripped core on
this modified yeast strain may introduce 2G12 sensitivity.
To ensure that the binding to CD4 binding site-directed antibodies was not an artifact of
yeast display, we secreted stripped core gp120 from HEK 293 cells both as a monomer and
as an Fc-fusion, and measured its binding to the single-chain variable fragment (scFv) of
VRC01 displayed on yeast. The equilibrium dissociation was found to be 8.7 nM for
monomeric stripped core and 1.1 nM for the dimeric Fc-fusion (FIG 1D), consistent with
previous titrations where the arrangement of gp120 and antibody was inverted.
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Mapping the VRC01 epitope with a random mutagenesis library.The broadly neutralizing
antibody VRC01 was used as a test case for epitope mapping with yeast-displayed stripped
core gp120. The crystal structure of the antibody in complex with gp120 from HIV strain
93TH057 has been solved (PDB ID: 3NGB)20 and can be used to validate mapping results.
The antibody is one of the broadest and most potent neutralizers of HIV yet discovered, and
a deeper understanding of its function many help inform immunogen design and guide the
search for new neutralizing antibodies.
We first mapped the VRC01 epitope using a library of randomly mutagenized gp120
molecules, as described previously47. The library was generated by PCR with an error-prone
polymerase under conditions of low mutagenesis. Its diversity was 7×107 members,
sufficient to sample all possible single amino acid substitutions at each of 285 positions.
Yeast displaying the gp120 library were incubated with 50 nM VRC01 and sorted for loss of
binding to the antibody. 0.6% of the original library was collected in this first sort, and a
second round at the same antibody concentration further enriched the population (FIG 2A,
2B).
A third round of sorting was performed with a conformational control antibody to exclude
allosteric mutations that ablate VRC01 binding from afar without making direct contact with
the antibody. gp120-specific antiserum from a mouse immunized with the stripped core
construct was used as a conformational control in this third sort.When the yeast library was
incubated with antiserum, only 5.5% of cells retained binding and were collected (FIG 2C).
This suggests that the majority of clones isolated in the VRC01 sorting rounds contained
allosteric mutations, and underscores the importance of a conformational control antibody.
To ensure that the antiserum in fact recognized conformational epitopes on the protein, yeast
displaying stripped core were first heated in the presence of 8 M urea to denature the protein
before binding was assayed. Antiserum bound the denatured stripped core more weakly than
it did the native protein (FIG 2D), suggesting that it recognized some conformational
epitopes on the protein. To ensure that the loss of binding was not due to fewer total proteins
present on the yeast cell surface, the binding signal was scaled by display signal from the
CMyc epitope tag.
Thirty-two clones from the library were sequenced after the third sort. Mutationsthat
introduced or replaced a cysteine or proline were removed from the analysis, as were
positions that were mutated only once. The remaining 21 mutations occurred at five
positions: 280, 368, 456, 458, and 469 in standard HxB2 numbering61. These positions fall
within the VRC01 footprint as defined by the antibody contact residues in crystal structure
3NGB (FIG 2E). Of the nine single mutations that were discarded from the analysis, one
(N278Y) resides in the VRC01 epitope and seven came from clones that also contained
either a VRC01 epitope mutation or a change to/from cysteine/proline.
The random mutagenesis epitope map is consistent with the structural epitope, but the
method requires access to a cell sorter and repeated rounds of sorting, sequencing and
analysis. To enable higher-throughput analysis of antibodies and antisera, we constructed a
small mutant library useful for rapid mapping of gp120-specific antibodies simply by flow
cytometry, without sorting, sequencing, or the need for a validated conformational control
antibody.
Making a defined mutant panel. We generated a homology model of stripped core gp120
with the protein structure modeling program MODELLER62, and 31 evenly-spaced surface
residues were chosen for mutagenesis. Amino acid substitutions were selected to be highly
disruptive based on differences in polarity, charge, and size. To guard against allosteric
mutations, only amino acids present with at least 0.1% frequency in the Los Alamos
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National Laboratory HIV Sequence Database were considered at each position. Thus,
prevalence in nature was used as a proxy for properly-folded gp120. The only exception to
this rule is the mutation D368R—a known CD4 binding site disruptor commonly used to
screen for CD4-directed antibodies from patient samples63—which is included in the library
though absent from the database. The location and identities of selected amino acid
substitutions are shown in FIG 3A, 3B and Table 1.
Mapping the VRC01 epitope with the mutant panel. The epitope of VRC01 was mapped
with the defined mutant panel. VRC01 was incubated with the library at 300 pM, and
binding signal analyzed using a plate-reader cytometer. Six mutations were found to disrupt
binding to VRC01: the expected D368R, as well as S365K, T455E, G459E, D461I, and
G473R (FIG 3C). These residues are consistent with the map from the random mutagenesis
library, and nicely overlay the antibody footprint as defined by crystal structure 3NGB (FIG
3B). The positions identified by the epitope map fall along the ridge comprised of the CD4
binding loop, variable loop V5, and beta strand β24, all known to be energetically important
for VRC01 binding64. Two mutations in loop D, T278K and K282V, were found not to
disrupt VRC01 binding to stripped core despite the fact that the loop appears to make
contact with VRC01 in the native trimer20.
An important consideration is that the quality of the map generated with this panel is
sensitive to the antibody concentration in the assay (FIG 3D). When the library was
incubated with VRC01 at 30 nM, only D368R showed any appreciable disruption of
binding. Incubations at 0.3 and 3 nM resulted in a clear distinction between the six
mutations listed above and all others. At lower VRC01 concentrations, this difference
diminished as the overall binding signal decreased across the board. Fitting binding
isotherms to the mapping data for each mutant illustrates this phenomenon (FIG 4A,
Supplementary Table 2). Non-epitope mutants have equilibrium binding constants between
0.1-1 nM, similar to that of wild-type stripped core gp120. By contrast, the KD for D368R
was greater than 100 nM, which explains why the mutant fails to bind at even the highest
tested concentrations of VRC01. A cluster of weaker mutations— the same S365K, T455E,
G459E, D461I, and G473R identified above—have a KD an order of magnitude higher than
wild-type gp120. There is a narrower window of antibody concentration for identifying
these five mutations in our screen.
Mapping other anti-gp120 antibodies. Two other important CD4-directed anti-gp120
antibodies, b12 and b13, were then mapped with the mutant panel. Antibody b12 is neither
as broadly cross-reactive nor as potent as VRC01 but for many years was the gold standard
of HIV neutralization. Antibody b13 also binds the CD4 binding site, but its offset
footprintrenders it incapable of binding trimeric gp120 envelope on HIV19and thus
incapable of neutralizing the virus.
Antibodies b12 and b13 were mapped over a range of concentrations near their KD (FIG 4B
and 4C, Table 2, and Supplementary Table 2). Mutations D368R, R419G, and T455E
strongly disrupt binding to b12, while mutations K282V, S365K, and I467K have weaker
effects. For b13, D368R is strongly disruptive and R419G is marginally so. When these
mutations are mapped onto the homology model, they are consistent with the contact
residues from the corresponding crystal structures (2ND7 and 3IDY, respectively) (FIG 4E,
4F).
The residues identified by epitope mapping by yeast surface display are also consistent with
those identified by previous mapping efforts reported in the literature. Amino acid
substitutions at positions 368 and 457 were found to disrupt binding of CD4 to gp12065.
Alanine scanning identified residues 365, 455, 458, and 473 as important for b12 binding66,
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and residues 474-476 for binding of CD4 binding site-reactive antibodies cloned from
infected individuals67. Computational analysis of envelope sequences found that
conservation at positions 364, 369 and 461 were indicative of b12 neutralization68.
Identification of combination mutants that bind differentially to VRC01, b12, and b13.
D368R ablates binding to all three CD4 binding site-directed antibodies tested, despite
variation in their epitopes and important phenotypic differences. The fine resolution
conformational epitope maps suggest that some of the weaker mutations may be more
specific disruptors than D368R, but they are very sensitive to antibody concentration. We
decided to combine the weaker mutations to see if they can act cooperatively to knock out
binding over a broader antibody concentration range while maintaining specificity.
Six constructs with either two or three mutations in combination were made by site-directed
mutagenesis and displayed on the surface of yeast (Table 3). The constructs were first
titrated against gp120-specific mouse antiserum (FIG 5A). For all constructs, the binding
thermodynamics were similar to that of D368R, suggesting that the multiple mutations do
not grossly disturb the overall protein structure.
The constructs were then titrated against antibodies VRC01, b12, and b13 (FIG 5B, 5C, 5D).
Multi-mutation construct MM3 (S365K, T455E, G473R) knocked out binding to VRC01
and b12 to a greater than or equal extent as canonical mutation D368R, but had no effect on
binding of b13. This construct may be useful for screening out b13-like antibodies that
approach the CD4 epitope at an angle not conducive to neutralization. Multi-mutation
construct MM5 (T459E, G473R) is even more specific for VRC01. It abrogates binding to
VRC01 more completely than D368R, but has negligible effects on both b12 and b13
binding. This construct may be useful for identifying precisely VRC01-like antibodies from
patient samples or immunization antisera.
Discussion
There is much effort in the HIV vaccine field to modify gp120 to make subunit vaccine
immunogens, and as bait to isolate and characterize antibodies from patient samples. Yeast
surface display is a simple and powerful tool for engineering complex glycoproteins43,44,46,
and random mutagenesis yeast-displayed libraries have been used for conformational
epitope mapping of EGFR 47, West Nile virus69, and influenza hemagglutinin70 previously.
In this work we demonstrate the display of a stripped core gp120 on yeast, and show by
binding to a panel of neutralizing antibodies that the vulnerable CD4 binding site epitope is
wellpresented. This platform enables rapid screening of candidate immunogens and high-
throughput analysis of serum samples.
As an example of the potential of yeast surface display, we have mapped the epitope of the
broadly neutralizing antibody VRC01 using a random mutagenesis library screened by
FACS. This is a convenient and established way to generate fine resolution maps of
conformational epitopes47,71-73. In the method, a random library of gp120 variants with
single point mutations is displayed on the surface of yeast and sorted for loss of binding to
the antibody. Mutants that disrupt binding likely form part of the epitope. We isolated
mutations at five positions—280, 368, 456, 458, and 469—that are consistent with the
known contact area of VRC01 from crystallography.
Because it can be difficult to distinguish mutations in the epitope from allosteric mutations
that disrupt the binding site at a distance, the random library method requires a
conformational control antibody that binds non-competitively elsewhere on the protein and
can report whether the molecule is correctly folded. In this work we relied upon gp120-
specific mouse antiserum collected in-house to eliminate mutations that allosterically disrupt
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VRC01 binding. The small fraction of the library (5.5%) that retained binding to serum after
having been sorted for loss of binding to VRC01 underscores how critical the
conformational control is.
A small mutant panel such as we constructed in this work has both advantages and
disadvantages relative to the random library screening approach described previously47. The
initial effort to identify a set of ~30 mutants is balanced against the relative speed with
which a given antibody can then be tested. A defined library of rationallychosen mutations,
though requiring more work to make, can be screened and analyzed without any DNA
sequencing, giving results in just a few hours.
VRC01 was mapped with the mutant panel, and the results were consistent with both the
random mutagenesis mapping and crystallography (FIG 4D vs. FIG 2E). It is important to
note that the quality of the map from the defined mutant panel is sensitive to the antibody
concentration in the assay (FIG 3D). This sensitivity is less evident with random library
mapping because only strongly disrupting mutations are isolated by that method. By
contrast, each mutant in the panel, although chosen to be disruptive, will have a particular
equilibrium binding constant. At too high a concentration all the isotherms are saturated and
will show similar binding signals. At too low a concentration, noise will make it impossible
to distinguish strong from weak binders.
Two other anti-gp120 antibodies, b12 and b13, were mapped with the mutant panel, and the
results agreed with crystallography. Crystal structures give accurate and detailed spatial
data; epitope mapping can provide additional information about epitope energetics. The
three mapped antibodies all bind the CD4 binding site but have significantly different
neutralization phenotypes. VRC01 is broadly neutralizing; b12 is weakly neutralizing; and
b13 is non-neutralizing. Our epitope map highlights the different energetically important
residues in the epitopes of these three antibodies.
One shared mutation among the three epitope maps is D368R, the canonical CD4 knockout
mutation. This mutation is widely used in the HIV vaccine field to test the specificity of
antibodies elicited by immunization and to screen patient samples for new neutralizing
antibodies15,17,26-28. Our mapping titrations indicate why this mutation is so favored. It
abrogates binding to all CD4-directed antibodies, and shifts the KD to such a degree that the
effect is observed regardless of the antibody concentration. This is particularly useful when
screening polyclonal antisera in which the precise concentration of individual antibodies is
unknown.
But the fact that D368R is common to all three epitope maps is also a detriment to its use,
because the mutation cannot distinguish between antibodies with similar epitopes but
significantly different phenotypes. Our mapping data suggests that combinations of some of
the weaker mutations may have equal potency but be more specific disruptors than D368R.
The multiple mutation construct MM3 (S365K, T455E, G473R) knocks out binding only to
VRC01 and b12, but not b13. The construct MM5 (T459E, G473R) abrogates binding to
VRC01 alone. These constructs may be useful for identifying precisely VRC01-like
antibodies from patient samples or immunization antisera. No binding assay can replace a
neutralization assay to determine antibody function, but improved specificity can help
improve the initial screen, particularly in cases where there may be limiting quantities of
serum (e.g. mouse immunization).
Methods
Display of gp120 on yeast. The gene for gp120 from HIV strain YU248 (Genbank Accession
No. M93258) was subcloned into the yeast display vector pCHA with a C-terminal Aga-2
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fusion partner with two epitope tags, CMyc (EQKLISEEDL) and HA (YPYDVPDYA). The
protein was displayed on Saccharomyces cerevisiae strain EBY100 using a standard surface
display protocol74. In brief, EBY100 yeast were transformed with plasmid (Frozen-EZ
Yeast Transformation II Kit, Zymo Research, Irvine, CA), grown to mid-log phase in SD-
CAA media at 30°C, and induced in galactose-containing SG-CAA media for 24 hr at 20°C.
Approximately 1×105gp120 molecules are displayed per yeast, as measured by quantitative
flow cytometry (data not shown).
Modifications to gp120.Antibody staining of epitope tags indicated that the full-length
gp120 was displayed on the surface of yeast, but no binding was observed to the antibody
b12 (data not shown). Extensive modifications were made to remove flexible loops that
might occlude the CD4 binding site or cause the protein to misfold. To this end, we removed
the flexible gp41-interactive region at the N- and C-termini (aa 1-89, 493-511)50 and
replaced the hyper-variable loops V1/V2 (aa 124-198), V3 (aa 298-329), and the bridging
sheet β20/21 (aa 422-437) with the short, glycosylated amino acid linkers, GNGS, GNGSG,
and GGNGS respectively. An additional double mutation (Q114N, L116T) introduced an N-
linked glycosylation sequence at a site previously identified as important for masking an
epitope on the V1/V2 stem35. All amino acid numbering is based on the HxB2 numbering
convention61.The full sequence is listed in Supplementary Table 1.
Secretion of gp120 from HEK 293 cells. The stripped core gp120 was subcloned into a
mammalian expression vector based on gWiz (Genlantis, San Diego, CA), either by itself or
downstream of the Fc domain of mouse IgG2a. All constructs also have a his6 tag. A
suspension culture of HEK 293 cells grown in serum-free medium (Freestyle 293, Life
Technologies, Carlsbad, CA) was transfected with DNA using PEI as per manufacturers
instructions. Supernatant was harvested after one week and purified on Talon metal affinity
chromatography resin (Clontech, Mountain View, CA) followed by size-exclusion
chromatography.
Making the random mutagenesis library. A random mutagenesis library was generated by
PCR with Mutazyme II error-prone polymerase (GeneMorph II Kit, Agilent, Santa Clara,
CA). To ensure a low mutagenesis rate, 400 ng target DNA was amplified for 24 cycles with
flanking primers. The re-amplified PCR product was combined with digested pCHA vector
and electroporated into EBY100 yeast, where the full plasmid was reassembled by
homologous recombination74. The final library size was estimated to be 7×107.
Homology modeling with MODELLER. The protein structure modeling program
MODELLER62 (http://salilab.org/modeller) was used to generate a homology model of the
yeast-displayed stripped core YU2 gp120. Though several crystal structures of gp120 exist
in the Protein Data Bank, none is an exact analog for the yeast-displayed molecule. We used
the crystal structure of gp120 bound by VRC01 (PDB ID: 3NGB, strain 93TH057) as a
structural template, though basing the model on alternate gp120 templates did not alter the
model significantly (Supplementary Figure 1).
Algorithm for selecting surface residues and amino acid substitutions for the mutant panel.
The homology model of stripped core gp120 was rendered in PyMOL (PyMOL Molecular
Graphics System, Version 1.2r3pre, Schrödinger, LLC.) and 31 evenly-spaced sites with
large solvent-exposed surface areas were selected for mutagenesis. Amino acid substitutions
were chosen to be highly disruptive of binding, yet not so disruptive as to misfold the
protein. We evaluated each amino acid substitution on three biophysical axes: polarity
(hydophobic, neutral, or polar), charge (negative, neutral, or positive), and size (greater than
or less than 160 Å2 surface area)75-77. A value of +1 was assigned for every unit step on
each axis, and the total disruption score was calculated by summing the net differences
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between two amino acids. Higher scores correspond to more disruptive changes. For
example, a mutation from glutamic acid to tyrosine would be scored +3 total: +2 for the
change from polar to hydrophobic, +1 for the change from negative charge to neutral, and
+0 for size because both surface areas are greater than 160 Å2.
To guard against allosteric mutations, we excluded all amino acid substitutions that are
present at less than 0.1% frequency in the Los Alamos National Laboratory HIV Sequence
Database (http://hiv.lanl.gov). An extremely disruptive mutation that that destroys the fold
of gp120 would likely ablate viral fitness too. The only exception to this rule is the mutation
D368R, a frequently used CD4 binding site disruptor, that is included in the library though
absent from the database.
Substitutions were made by site-directed mutagenesis. The mutant panel was limited to 31
clones and one wild-type stripped core gp120 so that three mappings could be performed on
a single 96-well plate on a high-throughput flow cytometer. A library with more members
would provide a finer resolution map at the cost of overall assay throughput.
Flow cytometry.Anti-gp120 antibodies were either produced from HEK cells or a generous
gift from Dennis Burton. CD4-Fc was purchased from Sino Biological (Beijing, China).
Yeast cells displaying protein were incubated with anti-gp120 antibodies and anti-epitope
tag antibodies, either mouse anti-HA (clone 16B12, Covance Inc., Emeryville, CA) or
chicken anti-CMyc (Gallus Immunotech, Fergus, Ontario). Secondary labeling was
performed with goat anti-mouse, -human, or -chicken antibodies conjugated to Alexa Fluor
dyes (Life Technologies, Carlsbad, CA) at recommended dilutions. Individual samples were
analyzed on an Accuri C6 cytometer (BD Accuri Cytometers, Ann Arbor, MI); 96-well
plates were run on a FACSCalibur HTS with a high-throughput plate sampler (Becton
Dickinson, Franklin Lakes, NJ); sorting was performed on a MoFlo instrument (Beckman
Coulter, Brea, CA).
gp120-specific mouse serum. Stripped core gp120 was secreted from HEK 293 cells as a
fusion to mouse IgG2a Fc, and purified by Talon affinity chromatography. The protein was
mixed with AddaVax (Invivogen, San Diego, CA) an oil-in-water emulsion adjuvant similar
to MF59 licensed for use in Europe. BALB/c mice (Charles River Laboratories,
Wilmington, MA) were immunized with 7.5 pmol gp120 subcutaneously at the base of the
tail, and boosted again six weeks later. Antisera were titrated on gp120-displaying yeast
(Figure 2D). A dilution of 1:200 saturated the yeast-displayed gp120, and was used as the
working dilution for antisera in all experiments in this report. To demonstrate
conformational specificity of the antisera, titrations were performed on yeast displaying
gp120 that had been incubated with 8 M urea and heated for 30 minutes at 82C to denature
the protein. In this assay, binding MFU were scaled by display MFU (CMyc epitope tag) to
ensure that the loss of binding signal was not due to fewer total proteins present on the yeast
cell surface.
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Highlights
• Engineered gp120 are used as immunogens and as bait for isolating anti-HIV
antibodies
• Stripped core gp120 presenting the CD4 epitope is displayed on the yeast cell
surface
• Rapid conformational epitope mapping of antibody VRC01 is performed by two
methods
• Mapping of b12 and b13 captures subtle energetic differences between similar
epitopes
• Maps suggest mutations that may better identify and assess neutralizing
antibodies
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Figure 1.
Yeast display of gp120. (a) Homology model of stripped core showing the inner domain
(white), outer domain (blue), the short glycosylated peptides that have replaced the V1/V2
loop (orange), V3 loop (red), and bridging sheet (purple), and the VRC01 contact residues
(yellow). Beneath it, a schematic of yeast display vector pCHA showing gp120, the C-
terminal Aga2 fusion partner, and two epitope tags. (b) Representative flow cytometry dot-
plot of yeast displaying stripped core gp120, bound to both an anti-CMyc antibody (x axis)
and the broadly neutralizing antibody VRC01 (y axis). (c) Binding isotherms of yeast-
displayed stripped core gp120 to a panel of CD4 binding site-directed antibodies.
Equilibrium KD values for the antibodies are as follows: VRC01, 0.8 nM; PGV04, 0.9 nM;
b12, 41 pM; b6, 24 pM; b13, 0.9 nM; CD4-Fc, 5.6 nM. (d) Binding of secreted stripped core
gp120 to yeast displaying the scFv of antibody VRC01. Equilibrium KD values for the
interactions are: Stripped Core, 8.7 nM; Fc Stripped Core, 1.1 nM.
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Figure 2.
Epitope mapping of VRC01 with a random mutagenesis library. (a-c) Sequential FACS
sorting plots of the library incubated with (a) 50 nM VRC01, (b) 50 nM VRC01, and (c) a
1:200 dilution of anti-gp120 antiserum. The fraction of total cells collected is shown on each
plot. (d) Titration of serum from an immunized mouse on yeast displaying gp120 (solid) and
yeast displaying gp120 whose structure has been disrupted by incubation with 8 M urea
(dashed).(e) Mutated residues from 32 sorted clones highlighted on the homology model of
stripped core gp120. Residues in red are the sequenced mutations; residues in yellow are the
contact region of VRC01 as determined from crystal structure 3NGB. The accompanying
table lists the mutations and their frequency.
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Figure 3.
Epitope mapping of VRC01 with a defined mutant panel. (a) Homology model of stripped
core gp120 with mutant panel residues shown in black. The contact surface of VRC01 from
crystal structure 3NGB is shown in yellow. (b) Close-up of the VRC01 epitope with select
residues in the mutant panel labeled and shown in red. (c) Binding of 300 pM VRC01 to the
mutant panel as measured by flow cytometry. Mutations are arranged in decreasing order of
binding MFU. (d) VRC01 binding to the mutant panel over a range of VRC01
concentrations. At the highest concentration (30 nM) only D368R disrupts binding. At the
lowest concentration (100 pM) it is difficult to distinguish differences in binding signal. At
intermediate concentrations, an epitope is well defined by loss of binding to: S365K, T455E,
G473R, G459E, D461I, and D368R.
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Figure 4.
Epitope mapping of CD4 binding site-directed antibodies. (a-c) Binding of antibodies
VRC01 (a), b12 (b), and b13 (c) to the defined mutant panel at a range of concentrations.
Monovalent equilibrium binding isotherms are fit to the data. Mutations that do not
significantly change the binding thermodynamics are shown in black. Those that weakly
disrupt binding are shown in red with dashed lines. Mutations that strongly disrupt binding
are drawn in solid red lines. Mutations are listed in Table 2. (d-f) Mutations that affect
binding to VRC01 (d), b12 (e), and b13 (f) are shown on the homology model of stripped
core gp120. Mutations that weakly disrupt binding are colored pink; those that strongly
disrupt binding are colored red. The contact residues of each antibody as defined by
crystallography are shown in yellow (VRC01, PDB ID 3NGB), orange (b12, PDB ID
2ND7), and blue (b13, PDB ID 3IDY) respectively.
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Figure 5.
inding of anti-gp120 antibodies to selective CD4 knockout mutants displayed on yeast.
Multi-mutant constructs MM3 (blue) and MM5 (red), stripped core (black), and stripped
core D368R (dashed black) are displayed on yeast, and binding to various antibodies is
assayed by flow cytometry: (a) gp120-specific mouse antiserum; (b) VRC01; (c) b12; (d)
b13. Mutations in multi-mutant constructs are listed in Table 3.
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Table 1
Point mutations in defined mutant panel
Library point mutations
N99Y E269G D397F T455E
K121T T278K R403V G459E
N197K K282V L405D D461I
V200K G327R R412V I467K
H216Y Q337V R419G G473R
K231T Q344V G434K R476V
T240K S365K Q442V K490S
L265R D368R S446K
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Table 2
Mutations that disrupt binding to CD4 binding site-directed antibodies.
Antibody Highly-disruptive
mutations
Weak
mutations
VRC01 D368R
S365K
T455E
G459E
D461I
G473R
b12
D368R
R419G
T455E
K282V
S365K
I467K
b13 D368R R419G
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Table 3
Point mutations in multi-mutant (MM) constructs for selective knockout of CD4 binding site-directed
antibodies.
Construct Mutations
MM1 S365K D461I G473R
MM2 S365K G459E G473R
MM3 S365K T455E G473R
MM4 T455E G473R
MM5 G459E G473R
MM6 D461I G473R
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